Moderna D
D
MRNA
246.890
USD
-3.92
(-1.56%)
Pre Open·252.480USD+5.590(+2.26%)
Last updated: · Delayed 15 min
Moderna net income 2016–2026What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
Moderna earned 162.00M USD in Q3 FY2026, the three months to 30 September 2026, against a loss of 200.00M USD on the same quarter a year before. Moderna made a net loss of 2.82B USD in fiscal year 2025, against a loss of 3.56B USD on the year before.
Last updated 6 Nov 2026 · Next report 12 Feb 2027
Net income
Net income Net margin
Growth
| Fiscal year | Period ending | Net income | Growth | Net margin | Revenue |
|---|---|---|---|---|---|
| TTM | 30 Sept 2026 | -2.79B | — | -110.46% | 2.53B |
| FY2025 | 31 Dec 2025 | -2.82B | — | -145.16% | 1.94B |
| FY2024 | 31 Dec 2024 | -3.56B | — | -111.32% | 3.20B |
| FY2023 | 31 Dec 2023 | -4.71B | -156.37% | -68.84% | 6.85B |
| FY2022 | 31 Dec 2022 | 8.36B | -31.47% | 44.30% | 18.88B |
| FY2021 | 31 Dec 2021 | 12.20B | — | 68.80% | 17.74B |
| FY2020 | 31 Dec 2020 | -747.06M | — | -92.99% | 803.40M |
| FY2019 | 31 Dec 2019 | -514.02M | — | -853.73% | 60.21M |
| FY2018 | 31 Dec 2018 | -384.73M | — | -284.84% | 135.07M |
| FY2017 | 31 Dec 2017 | -255.92M | — | -124.34% | 205.83M |
| FY2016 | 31 Dec 2016 | -216.21M | — | -199.46% | 108.40M |
| Quarter | Period ending | Net income | Growth on a year before | Net margin | Revenue |
|---|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 162.00M | — | 12.34% | 1.31B |
| Q2 FY2026 | 30 Jun 2026 | -782.00M | — | -539.31% | 145.00M |
| Q1 FY2026 | 31 Mar 2026 | -1.34B | — | -345.24% | 389.00M |
| Q4 FY2025 | 31 Dec 2025 | -826.00M | — | -121.83% | 678.00M |
| Q3 FY2025 | 30 Sept 2025 | -200.00M | -1,638.46% | -19.69% | 1.02B |
| Q2 FY2025 | 30 Jun 2025 | -825.00M | — | -580.99% | 142.00M |
| Q1 FY2025 | 31 Mar 2025 | -971.00M | — | -907.48% | 107.00M |
| Q4 FY2024 | 31 Dec 2024 | -1.12B | -616.13% | -117.15% | 956.00M |
| Q3 FY2024 | 30 Sept 2024 | 13.00M | — | 0.70% | 1.86B |
| Q2 FY2024 | 30 Jun 2024 | -1.28B | — | -578.73% | 221.00M |
| Q1 FY2024 | 31 Mar 2024 | -1.18B | -1,587.34% | -703.59% | 167.00M |
| Q4 FY2023 | 31 Dec 2023 | 217.00M | -85.19% | 7.71% | 2.81B |
| Q3 FY2023 | 30 Sept 2023 | -3.63B | -448.03% | -198.25% | 1.83B |
| Q2 FY2023 | 30 Jun 2023 | -1.38B | -162.81% | -401.16% | 344.00M |
| Q1 FY2023 | 31 Mar 2023 | 79.00M | -97.84% | 4.30% | 1.84B |
| Q4 FY2022 | 31 Dec 2022 | 1.47B | -69.91% | 28.45% | 5.15B |
| Q3 FY2022 | 30 Sept 2022 | 1.04B | -68.71% | 32.39% | 3.22B |
| Q2 FY2022 | 30 Jun 2022 | 2.20B | -20.97% | 48.12% | 4.57B |
| Q1 FY2022 | 31 Mar 2022 | 3.66B | +199.51% | 61.57% | 5.94B |
| Q4 FY2021 | 31 Dec 2021 | 4.87B | — | 70.05% | 6.95B |
| Q3 FY2021 | 30 Sept 2021 | 3.33B | — | 69.02% | 4.83B |
| Q2 FY2021 | 30 Jun 2021 | 2.78B | — | 65.95% | 4.22B |
| Q1 FY2021 | 31 Mar 2021 | 1.22B | — | 70.05% | 1.74B |
| Q4 FY2020 | 31 Dec 2020 | -272.49M | — | -47.74% | 570.75M |
| Q3 FY2020 | 30 Sept 2020 | -233.64M | — | -147.96% | 157.91M |
| Q2 FY2020 | 30 Jun 2020 | -116.71M | — | -175.90% | 66.35M |
| Q1 FY2020 | 31 Mar 2020 | -124.23M | — | -1,480.87% | 8.39M |
| Q4 FY2019 | 31 Dec 2019 | -123.29M | — | -877.20% | 14.06M |
| Q3 FY2019 | 30 Sept 2019 | -123.19M | — | -722.72% | 17.05M |
| Q2 FY2019 | 30 Jun 2019 | -135.05M | — | -1,032.29% | 13.08M |
| Q1 FY2019 | 31 Mar 2019 | -132.58M | — | -827.31% | 16.02M |
| Q4 FY2018 | 31 Dec 2018 | -141.43M | — | -399.27% | 35.42M |
| Q3 FY2018 | 30 Sept 2018 | -80.33M | — | -192.38% | 41.76M |
| Q2 FY2018 | 30 Jun 2018 | -90.60M | — | -314.03% | 28.85M |
| Q1 FY2018 | 31 Mar 2018 | -72.38M | — | -249.24% | 29.04M |
| Q4 FY2017 | 31 Dec 2017 | -37.94M | — | -41.29% | 91.90M |
| Q3 FY2017 | 30 Sept 2017 | -68.26M | — | -160.72% | 42.47M |
| Q2 FY2017 | 30 Jun 2017 | -80.08M | — | -224.15% | 35.72M |
| Q1 FY2017 | 31 Mar 2017 | -80.08M | — | -224.15% | 35.72M |
Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.
See also:Revenue,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement
Common questions about Moderna's profit
Source: Financial Modeling Prep